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ABSTRACT
Background: This study aimed to assess the salivary levels of interleukin‑8 (IL‑8) in oral lichen 
planus (OLP) and diabetes mellitus (DM) patients, and OLP + DM patients in comparison with 
healthy individuals.
Materials and Methods: This descriptive cross‑sectional study was conducted on 75 patients 
(30 with OLP, 5 with both OLP and DM, 20 with DM and 20 healthy controls). The salivary levels 
of IL‑8 and fasting blood sugar and 2‑h postprandial blood glucose levels were measured in all the 
subjects. Data were analyzed with one‑way ANOVA and post hoc least significant difference tests.
Results: The mean salivary level of IL‑8 was the highest in OLP + DM patients, followed by DM, 
OLP and control groups, respectively. Pair‑wise comparisons of the groups revealed significant 
differences in the salivary levels of IL‑8 between OLP and control, DM and control, also OLP + DM 
patients and control (P < 0.05).
Conclusion: The increasing salivary level of IL‑8 in the control, OLP, DM, OLP + DM groups, 
respectively, indicates the role of this inflammatory cytokine in the pathogenesis of OLP and diabetes.
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INTRODUCTION
The etiology of oral lichen planus (OLP) has yet 
to be clearly understood; however, there is a strong 
theory that T‑cell‑mediated immune responses are 
involved in its pathogenesis. Local and systemic 
release of different cytokines from blood cells and 
oral mucosal cells are responsible for the initiation 
and progression of OLP.[1] In recent years, the 
primary role of immune system in the development 
of this condition has become more prominent. 
Histopathological characteristics of the disease 
also confirm this theory. In general, OLP is a 
multifactorial condition and comprises a series of 
events that occur at different times during the course 
of disease.[2]
Interleukin-8 (IL-8) is an important mediator of 
host response to injury and inflammation. Its role 
is to activate neutrophils, neutrophil chemotactic 
factor, T cells and basophils. It is produced by 
different cells, including monocytes/macrophages, 
T cells, neutrophils, endothelial cells, fibroblasts 
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and keratinocytes during the inflammatory and 
pathological processes.[3]
The concentration of IL-8 is insignificant in 
healthy tissues; however, its level rapidly reaches 
10–100 times its baseline value in response to 
pro-inflammatory cytokines, namely tumor necrosis 
factor-alpha (TNF-α) and IL-1 as well as bacterial 
or viral products and cellular stress. In patients 
with OLP, keratinocytes also produce IL‑1 and 
TNF‑α.[4] Moreover, mononuclear cells infiltrating 
around the OLP mucosal lesions can produce TNF‑α.[5] 
Keratinocytes, macrophages, T-cells, endothelial cells 
and fibroblasts stimulated by IL-1 and TNF-α in OLP 
lesions can release significant amounts of IL-8. This 
cytokine further enhances the infiltration of T cells, 
particularly cytotoxic T cells, around OLP lesions; 
therefore, it plays a role in the pathogenesis of OLP.[6]
Rhodus et al.[7] demonstrated that the salivary and 
serum levels of IL-8 were significantly higher in 
OLP patients compared to healthy individuals. Zhang 
et al.[8] showed that salivary and serum levels of IL-8 
and other pro-inflammatory cytokines were higher 
in OLP patients compared to healthy subjects and 
suggested that saliva can be an efficient alternative 
to serum for testing pro-inflammatory cytokines in 
OLP patients. Sun et al.[6] reported that IL-8 levels 
were significantly higher in OLP patients compared 
to healthy controls and concluded that IL-8 is a more 
sensitive marker than IL‑6 for the detection of OLP.
Noninsulin-dependent diabetes mellitus (DM) 
or type II diabetes is the most common form of 
diabetes and results from a combination of obesity, 
inflammation and hyperglycemia.[9]
Zozuliñska et al. in 1999 reported that the serum levels 
of IL-8 in diabetics were significantly higher than 
those in nondiabetics.[10] At high glucose levels, IL-8 
is produced following the adhesion of monocytes to 
endothelial cells in diabetic patients.[11] Subsequently, 
increased IL-8 levels enhance the inflammatory 
reactions in DM patients. In fact, a vicious circle is 
created within which IL-8 and increased glucose 
levels mutually affect each other.
A relationship between DM and lichen planus seems 
possible[12] and evidence shows that such correlation 
might exist.[1,2,13,14] However, previous studies in 
this regard are different in terms of methodology 
and have yielded controversial results.[12-14] Seyhan 
et al.[9] reported that half of the patients with OLP have 
impaired glucose metabolism and ¼ suffer from DM.
Based on previous studies, IL-8 has a potential role in 
OLP and DM. Thus, this study aimed to measure the 
salivary level of IL-8 in 4 groups of OLP, DM, OLP, 
and DM and healthy controls. Considering the possible 
role of IL-8 in both conditions, IL-8 levels might be 
higher in subjects suffering from both conditions. If 
this hypothesis is accepted, we may be able to take a 
step forward in the treatment of these patients by new 
modalities and host immunomodulation.
MATERIALS AND METHODS
This study was approved in the Ethics Committee of 
Isfahan University of Medical Sciences, School of 
Dentistry. This descriptive, analytical, cross‑sectional 
study was conducted on patients with OLP, DM, 
and both conditions as well as healthy controls. 
The patients were chosen from those presenting to 
the Dental Clinic of School of Dentistry, Isfahan 
University of Medical Sciences and private dental 
clinics in Isfahan.
Healthy controls were selected from subjects 
presenting to the laboratories for regular checkups, 
who had no history of drug intake or systemic 
diseases.
Diabetic patients were selected among those referred 
to the Diabetes Center, suspected of having type II 
diabetes. These patients had fasting blood sugar (FBS) 
≥126 mg/dL or 2-h postprandial blood glucose (2 hpp) 
≥200 mg/dL and also exhibited the clinical symptoms 
of diabetes, including polyphagia, polydipsia and 
polyuria.[15] These patients were not on medication 
and had no other systemic diseases.
Patients with symptomatic OLP were selected from 
those presenting to the Dental Clinic of School of 
Dentistry, Isfahan University of Medical Sciences and 
private dental clinics in Isfahan. After observing the 
red and white patches by an oral medicine specialist 
and taking a history, a biopsy was taken. Based on the 
pathology report, clinical diagnosis of the clinician and 
patient history, patients with OLP were differentiated 
from those with lichened reactions according to 
the World Health Organization criteria.[16] Patients 
with lichenoid drug reactions, contact dermatitis, 
graft versus host disease and cutaneous lesions were 
excluded from the study.
FBS and 2 hpp blood glucose tests were performed 
for patients with OLP and based on the test results 
they were assigned to OLP or OLP plus DM groups. 
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This process continued until a sample size of 35 
subjects was achieved.
Patients taking medications, suffering from 
systemic conditions other than DM and OLP, with 
inflammation in other parts of the body and also those 
with periodontal diseases were excluded from the 
study. Cigarette smoking, substance abuse and alcohol 
consumption were also among the exclusion criteria 
for the four groups.
However, considering the fact that DM and gingival 
inflammation exacerbate each other in a vicious 
circle,[17] complete exclusion of DM patients with 
gingival inflammation was not feasible. However, 
we tried our best to exclude DM patients with severe 
gingival inflammation.
After 8 h of fasting, 3 mL of blood was obtained 
between 7 and 9 a.m. (to prevent circadian effects) 
from subjects and they were asked to have a 
regular (carbohydrate) breakfast in 5–10 min and come 
back 2 h after the breakfast for 2 hpp blood glucose 
test. The subjects were requested to refrain from any 
vigorous physical activity during this time. After 
obtaining FBS and before having breakfast, 3 mL of 
saliva was collected from each patient. Unstimulated 
salivary samples were obtained using the spitting 
technique. The blood samples obtained from the 
patients were centrifuged immediately after clotting at 
3000 rpm for 15 min. FBS and 2 hpp blood glucose 
levels were measured using the separated plasma. The 
salivary samples were immediately stored at −20°C 
for later measurement of IL-8 concentration using the 
ELISA kit (Quantikine ELISA, R and D Systems Inc., 
USA and Canada).
RESULTS
Twenty type II DM patients, 20 healthy controls and 
35 OLP patients were evaluated. In OLP patients, 
14.28% had type II diabetes; in addition, 20% of 
OLP patients had impaired FBS, 100–125 mg/dL). 
As observed in Table 1, the mean salivary level 
of IL-8 was the highest in patients with both 
OLP and type II diabetes (417.12 ± 43.9 pg/mL), 
followed by DM group (382.35 ± 95.7 pg/mL), 
OLP group (314.31 ± 83.8 pg/mL) and the control 
group (254.3 ± 77.05 pg/mL).
One-way ANOVA showed significant differences 
between the groups in salivary levels of 
IL-8 (P = 0.001).
Post hoc least significant difference test was then 
applied, revealing that significant differences existed 
in the salivary levels of IL-8 between the OLP 
and control groups (P = 0.016), type II DM and 
control groups (P < 0.001), control and OLP + DM 
groups (P < 0.001) and also OLP and OLP + DM 
groups (P = 0.013). Although the mean concentration 
of IL-8 in the saliva of OLP + DM patients was higher 
than that in type II diabetes group, this difference was 
not statistically significant (P = 0.41).
The mean FBS and 2 hpp blood glucose values were the 
highest in OLP patients with DM, followed by DM, OLP 
and control groups, in a descending order [Table 2].
DISCUSSION
First objective: Comparison of interleukin‑8 
salivary levels between the oral lichen planus 
patients and the control group
The etiology of OLP has yet to be fully 
understood. However, a strong theory suggests 
that T-cell-mediated immune responses (band-like 
infiltrates of macrophages and CD4+ cells in the initial 
phases and dominance of CD8+ cells in later stages) 
are involved in its pathogenesis. Local and systemic 
release of different cytokines from the oral mucosal 
cells and blood cells are responsible for the initiation 
and progression of OLP.[1]
For years, researchers have attempted to find a 
suitable noninvasive method for constant monitoring 
of the course of lichen planus and its treatment. 
Many previous studies have searched for an 
accurate, cost‑effective and noninvasive diagnostic 
technique for the assessment of cytokines related to 
this disease in blood and other diagnostic media.
The current study showed that the mean salivary level 
of IL-8 was significantly higher in OLP patients than 
the control group (P = 0.016).
Table 1: The mean (± standard deviation) changes in the salivary levels of IL‑8 in the 4 study groups
IL-8 salivary concentration (pg/mL) Control OLP and type II DM Type II DM OLP
Range of changes 89‑381 356‑480 219.6‑618.2 202.9‑512
Mean±SD 254.3±77.05 417.12±43.9 382.35±95.7 314.31±83.8
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Rhodus et al.[18] stated that salivary and serum levels of 
IL-8 were significantly higher in patients with lichen 
planus than the control group and also mentioned that 
IL-8 possesses diagnostic and monitoring capabilities 
and can help with the treatment planning process.
Zhang et al.[8] reported that IL-8 level in the oral 
fluids of OLP patients was significantly higher than 
that in healthy controls and stated that evaluation 
of saliva samples is an efficient technique to detect 
high levels of cytokines related to OLP compared to 
the assessment of serum. They also mentioned that 
salivary IL-8 is a reliable biomarker for the assessment 
of the severity of OLP. Tavangar et al.[19] showed that 
serum level of IL-8 in OLP patients was significantly 
higher than that in healthy individuals (P = 0.002).
Increased salivary concentrations of cytokines in 
OLP patients might be attributed to their increased 
release by the inflammatory cells or keratinocytes.[20] 
On the other hand, injured oral mucosa (particularly 
in erosive lichen planus) can no longer act as a 
protective barrier and this issue may also contribute 
to the increase in salivary levels of cytokines.
In OLP patients, keratinocytes also produce IL‑1 and 
TNF‑α.[6] Moreover, mononuclear cells infiltrating 
the tissue around OLP mucosal lesions can release 
TNF‑α.[5] Keratinocytes, macrophages, T cells, 
endothelial cells and fibroblasts stimulated by IL-1 
and TNF‑α in OLP lesions can release significant 
amounts of IL-8. This cytokine further enhances the 
infiltration of T cells, particularly cytotoxic T cells, 
at the site of OLP lesions, thus playing a role in the 
pathogenesis of OLP.[6]
Second objective: Comparison of interleukin‑8 
salivary levels between the type II diabetic 
patients and the control group
In this study, the mean salivary level of IL-8 in 
diabetic patients was significantly higher than that 
in healthy controls (P < 0.001). Several studies have 
reported significantly higher serum levels of IL-8 in 
patients with DM than healthy controls.[10,11] Since 
factors present in the serum also enter saliva, it may 
be concluded that high serum levels of IL-8 can 
also increase its salivary concentration. Zozuliñska 
et al. in 1999 reported that the serum level of IL-8 
in diabetics was significantly higher than that in 
nondiabetics.[10] At high glucose concentrations, IL-8 
is produced following the adhesion of monocytes to 
endothelial cells in diabetic patients.[11] Subsequently, 
increased IL-8 levels enhance the inflammatory 
reactions in DM patients. In fact, a vicious circle is 
created within which IL-8 and increased glucose 
levels mutually affect each other. Saliva is a complex 
combination of salivary gland secretions, crevicular 
fluid, etc;[21] and obviously IL-8 concentration is 
influenced by these sources. For instance, oral 
inflammation increases the salivary concentration of 
IL-8.[22,23]
Third objective: Occurrence of diabetes mellitus 
and glucose impairment in oral lichen planus 
patients
Previous studies have yielded controversial results in 
this respect; which might be attributed to differences 
in the methodologies and designs of studies. Atefi 
et al.[24] in 2012 reported a prevalence rate of 20% 
for DM in patients with OLP. Furthermore, they 
reported the incidence of impaired FBS to be 17.5% 
(100–125 mg/dL). Ansar and Ghasemzadeh[25] in 2012 
reported a prevalence of 3.3% for DM in OLP patients 
in Iran. In this study, 14.2% of OLP patients had DM. 
Impaired FBS was seen in 20% of OLP patients. 
Higher prevalence of glucose intolerance in the OLP 
compared to the control group indicates the possible 
role of glucose intolerance in the pathogenesis of 
lichen planus.[26]
Fourth objective: Comparison of interleukin‑8 
salivary levels between patients with both oral 
lichen planus and diabetes mellitus and other 
groups
In our study, salivary concentration of IL-8 in patients 
with OLP and DM was significantly higher than 
that in the control and OLP groups (P < 0.05). The 
increasing salivary and serum levels of IL-8 in the 
control, OLP and OLP + DM groups, respectively, 
indicate the role of this inflammatory cytokine in 
the pathogenesis of OLP and DM and the synergistic 
effect in patients suffering from OLP and DM.
As we have seen no study is available on salivary 
levels of IL-8 in four groups simultaneously. This 
study follows the research carried out by the same 
Table 2: The mean FBS and 2 hpp blood glucose 
values in the 4 study groups
Group Mean FBS 
(mg/dL)
Mean 2 hpp blood glucose 
(mg/dL)
OLP + DM 159.25±49.3 224.35±62.2
DM 152.8±26.6 210.2±44.8
OLP 99.85±14.4 109.95±36.92
Control 92.83±12.01 104.56±32.2
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researcher on the serum levels of IL-8 in these four 
groups. Tavangar et al. research that was carried 
out in the same patients showed that the serum 
levels of IL-8 in OLP patients and OLP + DM 
patients were significantly higher than those in 
healthy people (P < 0.05). Although the mean serum 
concentration of IL-8 in diabetic patients was more 
than that in the control groups, the differences were 
not statistically significant. In the current study, 
salivary levels of IL-8 in OLP patients, diabetic and 
OLP + DM patients were significantly higher than 
those in healthy individuals. It seems that salivary 
sampling is more convenient and noninvasive than 
serum sampling. The salivary sampling method can 
be an adjunctive or alternative method of serum 
sampling.
One of the limitations of this study was a lack of 
cooperation for taking part in this study and difficulty 
finding sufficient qualified OLP patients. In addition, 
despite the inclusion of patients without systemic or 
inflammatory diseases, elimination of mild internal 
inflammation was not possible that might have a 
minor effect on IL-8 level.
Future studies with larger sample sizes are required 
to assess and compare the salivary levels of IL-8 in 
different forms of OLP and investigate its effect on 
the clinical course of the disease.
CONCLUSION
Salivary levels of IL-8 increases in both OLP and 
DM as a pro-inflammatory cytokine, but its levels are 
significantly higher in patients with both conditions. 
Regulation of this inflammatory factor might lead 
to an improvement in clinical symptoms of OLP, 
especially OLP + DM.
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